CA2996614C - Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases - Google Patents
Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases Download PDFInfo
- Publication number
- CA2996614C CA2996614C CA2996614A CA2996614A CA2996614C CA 2996614 C CA2996614 C CA 2996614C CA 2996614 A CA2996614 A CA 2996614A CA 2996614 A CA2996614 A CA 2996614A CA 2996614 C CA2996614 C CA 2996614C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- hypoxia
- tpen
- alginate
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562208914P | 2015-08-24 | 2015-08-24 | |
| US62/208,914 | 2015-08-24 | ||
| PCT/US2016/051482 WO2017035542A1 (en) | 2015-08-24 | 2016-09-13 | Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2996614A1 CA2996614A1 (en) | 2017-03-02 |
| CA2996614C true CA2996614C (en) | 2023-12-12 |
Family
ID=58101120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2996614A Active CA2996614C (en) | 2015-08-24 | 2016-09-13 | Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10653685B2 (https=) |
| EP (1) | EP3340985B1 (https=) |
| JP (1) | JP6849683B2 (https=) |
| CN (1) | CN108076628A (https=) |
| AU (1) | AU2016311504A1 (https=) |
| CA (1) | CA2996614C (https=) |
| IL (1) | IL257689B (https=) |
| WO (1) | WO2017035542A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022246503A1 (en) * | 2021-05-24 | 2022-12-01 | The Florey Institute Of Neuroscience And Mental Health | Methods for mediating vasoconstriction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89349A0 (en) * | 1989-02-20 | 1989-09-10 | Hadassah Medical Organisation | Pharmaceutical composition for protecting the heart comprising a heterocyclic ethylenediamine derivative and methods for the use thereof |
| IL155111A0 (en) * | 2003-03-27 | 2003-10-31 | Yerachmiel Yori Applebaum | Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof |
| CN100393367C (zh) | 2003-05-05 | 2008-06-11 | 宾-古里安尼格夫大学研究及发展部 | 可注射的交联聚合制剂及其应用 |
| EP2136783B1 (en) * | 2007-03-13 | 2013-04-24 | Biolinerx Ltd. | A method of promoting muscle tissue repair |
| US20120276152A1 (en) * | 2011-04-29 | 2012-11-01 | Syed Hossainy | Systems and methods of using zinc-chelator to treat myocardial infarction |
| WO2013003445A1 (en) | 2011-06-30 | 2013-01-03 | Athena Cardionet Ltd. | Tetra-pyridine compounds and composition for protecting cells, tissues and organs against ischemia-reperfusion injury |
-
2016
- 2016-09-13 AU AU2016311504A patent/AU2016311504A1/en not_active Abandoned
- 2016-09-13 JP JP2018530677A patent/JP6849683B2/ja active Active
- 2016-09-13 CN CN201680049299.7A patent/CN108076628A/zh active Pending
- 2016-09-13 EP EP16840266.7A patent/EP3340985B1/en active Active
- 2016-09-13 CA CA2996614A patent/CA2996614C/en active Active
- 2016-09-13 WO PCT/US2016/051482 patent/WO2017035542A1/en not_active Ceased
- 2016-09-13 US US15/755,262 patent/US10653685B2/en active Active
-
2018
- 2018-02-22 IL IL257689A patent/IL257689B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN108076628A (zh) | 2018-05-25 |
| AU2016311504A1 (en) | 2018-03-08 |
| IL257689A (en) | 2018-04-30 |
| IL257689B (en) | 2021-03-25 |
| EP3340985A4 (en) | 2019-04-10 |
| US10653685B2 (en) | 2020-05-19 |
| JP2018527407A (ja) | 2018-09-20 |
| WO2017035542A1 (en) | 2017-03-02 |
| JP6849683B2 (ja) | 2021-03-24 |
| CA2996614A1 (en) | 2017-03-02 |
| US20180243276A1 (en) | 2018-08-30 |
| EP3340985A1 (en) | 2018-07-04 |
| EP3340985B1 (en) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI577379B (zh) | 含有海藻糖之預防肺栓塞用哺乳動物細胞懸浮液 | |
| CN102379872A (zh) | 抑制α-突触核蛋白毒性的化合物、组合物和方法 | |
| CN109803647A (zh) | α-丁酮酸、α-酮戊二酸和2-羟基丁酸用于刺激毛发生长 | |
| EP3154551B1 (en) | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject | |
| CA2996614C (en) | Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases | |
| EP2776058B1 (en) | Apotransferrin for the treatment of brain stroke | |
| CN104902891B (zh) | 治疗和预防创伤性脑损伤性神经元损害的组合物和方法 | |
| US20250099491A1 (en) | Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids | |
| EP3763362B1 (en) | Method of treating idiopathic pulmonary fibrosis | |
| EP3782620B1 (en) | Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia | |
| CN107205944A (zh) | 用于纠正衰弱和/或慢性疲劳综合征的症状或治疗衰弱和/或慢性疲劳综合征的药物组合物 | |
| WO2015084706A1 (en) | Intra-articular formulations and methods for treatment of osteoarthritis | |
| CN104524544A (zh) | 一种多肽在治疗糖尿病中的应用 | |
| KR100817932B1 (ko) | 베르바민을 유효성분으로 포함하는 혈관 재협착 예방제 | |
| CN103861091A (zh) | 治疗膀胱炎的药物组合物 | |
| WO2016074203A1 (zh) | 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途 | |
| WO2022199551A1 (en) | Dc009 for treating acute ischemic stroke | |
| US20230302042A1 (en) | Methods for the prevention of cholesterol crystal embolization with cyclodextrins | |
| EA046226B1 (ru) | Применение фармацевтической композиции в качестве лекарственного средства для защиты и/или репарации/восстановления гематоэнцефалического барьера | |
| US20120295858A1 (en) | Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder | |
| CN120884591A (zh) | 达克罗宁和/或其衍生物在制备治疗复苏后脑损伤药物中的应用 | |
| US20100286074A1 (en) | Pharmaceutical use of ginsenoside or mixture thereof and pharmaceutical composition of ginsenoside and use thereof | |
| WO2025053283A1 (ja) | ベルベルビン関連化合物 | |
| CN119745887A (zh) | 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用 | |
| CN101904843B (zh) | 化合物制备骨破坏抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210909 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240910 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240910 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240910 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |